Month: February 2021

DNA PLC STOCK EXCHANGE RELEASE 2 FEBRUARY 2021, 8:30 AM EETThis is a summary DNA’s Financial Statements Bulletin 2020. The complete report is attached to this release and also available at www.dna.fi/investors.SummaryUnless otherwise stated, the comparison figures in brackets refer to the corresponding period in the previous year (reference period). Figures are unaudited.Due to delisting of DNA’s share from Nasdaq Helsinki on 3 February 2020, DNA is not subject to reporting obligations as an issuer of shares as set out in the Finnish Securities Markets Act. DNA is still subject to reporting obligations as an issuer of senior unsecured fixed rate notes due 2025 (ISIN: FI4000312095) listed in Nasdaq Helsinki stock exchange.July–December 2020Mobile revenue increased 1% and amounted to EUR 276 million (272).Total revenues decreased 2% and...

DNA OYJ PÖRSSITIEDOTE 2.2.2021 KLO 8.30Tämä tiedote on tiivistelmä DNA:n tilinpäätöstiedotteesta 2020. Tilinpäätöstiedote kokonaisuudessaan on tämän pörssitiedotteen liitteenä pdf-tiedostona ja verkkosivuillamme, osoitteessa www.dna.fi/sijoittajat.YhteenvetoSuluissa olevat luvut viittaavat vastaavaan ajanjaksoon vuotta aiemmin, ellei toisin mainita. Luvut ovat tilintarkastamattomia.DNA:n osakkeen listaus Nasdaq Helsingin pörssissä päättyi 3.2.2020 ja tämän jälkeen DNA ei ole arvopaperimarkkinalain mukaisen tiedonantovelvollisuuden piirissä osakkeiden liikkeeseenlaskijana. DNA on laskenut liikkeelle vuonna 2025 erääntyvän joukkovelkakirjalainan (ISIN: FI4000312095), joka on listattuna Nasdaq Helsingin pörssissä ja jonka suhteen DNA on edelleen tiedonantovelvollisuuden piirissä.Heinä–joulukuu 2020Matkaviestinliikevaihto kasvoi 1 % ja oli...

Zaandam, the Netherlands, February 2, 2021 – Ahold Delhaize today announces the nomination of Jan Zijderveld for appointment to Ahold Delhaize’s Supervisory Board, effective April 14, 2021.  Jan Zijderveld is a Dutch national, who spent almost 30 years at Unilever holding several senior management positions in 7 different countries, ending up as CEO & President of Unilever Europe and member of Unilever executive team. Jan served as Chief Executive Officer of Avon as of 2018 and left the company in 2020 after a successful turnaround of its business ultimately resulting in an acquisition of the company by The Natura & Co. Currently Jan holds several advisory functions.  “We are pleased to propose Jan for appointment to the Supervisory Board. He will bring extensive international experience, consumer insights in a broad range of...

MONT-SAINT-GUIBERT, Belgium, Feb. 02, 2021 (GLOBE NEWSWIRE) — Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the company plans to participate at the following conferences in February 2021:CAR-TCR Digital Summit EuropeDate: Wednesday, February 17, 2021Time: 2:00 p.m. GMT / 3 p.m. CETSVB Leerink Partners Global Healthcare ConferenceDate: Thursday, February 25, 2021Time: 4:20 p.m. – 4:50 p.m. ET / 10:20 p.m. – 10:50 p.m. CETWebcast: A live and archived webcast of the presentation will be available in the Events section of the Celyad Oncology websiteAbout Celyad OncologyCelyad Oncology is a clinical-stage biotechnology company focused on the discovery and development...

WISeKey Delivers Secure Microcontrollers for LEGIC’s Multi-Purpose Security Modules / Reader ICsGeneva – February 2, 2021 – WISeKey International Holding Ltd (“WISeKey”, SIX: WIHN / Nasdaq: WKEY), a leading cybersecurity, AI and IoT company, today announced that is has delivered microcontrollers from its MicroXsafe range to LEGIC Identsystems (“LEGIC”), a Swiss-based provider of a Security Platform for smartphone- and smartcard-based access, mobility, shared resource and industrial IoT applications.“We are proud to continue to work with LEGIC, a valued customer for the past six years, to develop highly secured microcontrollers. Our cooperation with LEGIC in the secure microcontroller range is a strong recognition of our unparalleled expertise in developing innovative products specifically designed to support our clients’ unique...

PRESS RELEASE: 2 February 2021, 07:00 CETNew US Studies Demonstrate Idylla™ Allows Rapid First Assessment of Most Common EGFR Mutations Preceding Next-Generation SequencingMechelen, Belgium, 2 February 2021 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces the publication of two recent studies by Memorial Sloan Kettering Cancer Center (‘MSKCC’, New York, US) on the use of Biocartis’ Idylla™ EGFR Mutation Assay (RUO1) as a rapid first-line testing method before using next-generation sequencing (NGS). Both studies conclude that Idylla™ EGFR testing enables rapid assessment of the most common EGFR mutations with low sample input, even on different sample types, without compromising subsequent more comprehensive NGS testing, which can be useful...

PERSBERICHT: 2 februari 2021, 07:00 CETNieuwe VS studies tonen aan dat Idylla™ snelle eerste beoordeling toelaat van meest voorkomende EGFR mutaties, voorafgaand aan next-generation sequencingMechelen, België, 2 februari 2021 – Biocartis Group NV (de ‘Vennootschap’ of ‘Biocartis’), een innovatief bedrijf in de moleculaire diagnostiek (Euronext Brussels: BCART), kondigt vandaag de publicatie aan van twee recente studies door Memorial Sloan Kettering Cancer Center (‘MSKCC’, New York, VS) over het gebruik van de Idylla™ EGFR Mutation Assay (RUO1) van Biocartis als snelle eerstelijns testing methode alvorens next-generation sequencing (NGS) te gebruiken. Beide studies besluiten dat de Idylla™ EGFR test een snelle beoordeling van de meest voorkomende EGFR-mutaties mogelijk maakt met een beperkte staalinput, zelfs op verschillende soorten...

Allschwil, Switzerland – February 2, 2021Idorsia Ltd (SIX: IDIA) today reported the results of an arbitration proceeding between Actelion Ltd (“Actelion”) and the assignee of certain former Axovan shareholders (the “Claimant”) claiming that the acquisition of Actelion by Johnson & Johnson and/or the Demerger triggered the accelerated payment of all outstanding milestones mainly relating to clazosentan (the “Claim”).Idorsia was notified that the Claim had been dismissed by the Arbitral Tribunal in its final award dated February 1, 2021.Idorsia remains fully committed to developing and commercializing clazosentan and to paying any milestones, if and when due.Further commentary will be given during the company’s full year financial results 2020 webcast and conference call which is scheduled for Thursday, February 4, 2021 at 14:00 CET...